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An Evidence-Based Approach to the Management of
Chronic Constipation in North America
American College of Gastroenterology Chronic Constipation Task Force
Chronic constipation (CC) is characterized by unsatisfac-
tory defecation that results from infrequent stools, difficult
stool passage, or both. The pathophysiology of CC is multi-
factorial and may include dysfunction of intestinal motility,
visceral sensitivity, ano-rectal musculature and the enteric
nervous system. Because CC is common, this monograph
has been developed to educate physicians about its epidemi-
ology, diagnostic approach, and treatment.
In order to assess published data about the management of
CC, systematic reviews were performed. Standard criteria for
systematic reviews were met, including comprehensive liter-
ature searching, use of pre-specified study selection criteria,
and use of a standardized and transparent process to extract
and analyze data from studies (Section 2.1). A North Ameri-
can perspective was chosen: only epidemiologic studies from
North American populations were used and only treatments
available in the United States were examined. After analy-
sis of the systematic reviews, Task Force members produced
evidence-based recommendations (Section 2.2). Recommen-
dations were graded using a formalized system (Table 1.1)
that quantifies the strength of evidence. Recommendations
in this monograph may be cross-referenced with the sup-
porting evidence in the following article: “Systematic Re-
view on the Management of Chronic Constipation in North
America.” The format of this evidence-based position mono-
graph and systematic review has been adapted from the pre-
vious evidence-based monograph produced by the American
College of Gastroenterology’s Functional GI Disorders Task
Force (1).
SYMPTOM-BASED CRITERIA FOR CHRONIC
CONSTIPATION AND THRESHOLD TO TREAT CHRONIC
CONSTIPATION (SEE SECTION 2.3)
Constipation is a symptom-based disorder defined as unsatis-
factory defecation and is characterized by infrequent stools,
difficult stool passage, or both. Difficult stool passage in-
cludes straining, a sense of difficulty passing stool, incom-
plete evacuation, hard/lumpy stools, prolonged time to stool,
or need for manual maneuvers to pass stool (Grade C Recom-
mendation). CC is defined as the presence of these symptoms
for at least 3 months (Grade C recommendation). Available
evidence indicates that self-reported constipation is associ-
ated with decreased quality of life (Grade C recommenda-
tion). Treatment of patients with CC is indicated when the
symptoms diminish quality of life (Grade C recommenda-
tion).
Chronic functional constipation has been defined as a
symptom-based disorder by an international committee that
had its meeting in Rome. These symptom-based so-called
“Rome criteria” emphasize ≥12 wk/year of symptoms, in-
cluding hard or lumpy stools, straining, a sense of incom-
plete evacuation, the need to use manual maneuvers to pass
stool, or a sense of anorectal obstruction with ≥25% of bowel
movements, and/or <three bowel movements/week, with no
evidence of organic disease. At least two symptoms should
be present to make the diagnosis of chronic functional con-
stipation. Although the Rome criteria may identify a uniform
group of study patients for a constipation treatment trial, ex-
pert opinion suggests that widespread use of these criteria
is impractical. Observational studies indicate that most pa-
tients who report constipation symptoms do not fulfill Rome
criteria for chronic functional constipation. Therefore, Task
Force members recommended a broader definition that en-
compasses the symptoms most commonly expressed by pa-
tients who self-report constipation.
Observational studies and expert opinion indicate that CC
frequently overlaps with IBS with constipation; the latter is
defined as the presence of clinically important abdominal
discomfort associated with constipation symptoms. Patients
with CC may report minimal abdominal bloating or discom-
fort associated with their other CC symptoms, creating a spec-
trum between CC and IBS. In some patients it may be difficult,
if not impossible, to differentiate CC and IBS accurately and
reliably.
Observational studies of patients who self-report CC sug-
gest that CC is associated with a decreased quality of life.
Treatment of CC should be instituted when both the patient
and physician have determined that the symptoms diminish
the patient’s quality of life.
EPIDEMIOLOGY OF CHRONIC CONSTIPATION IN NORTH
AMERICA (SEE SECTION 2.4)
Estimates of the prevalence of CC in North America vary
between 2% and 27%. This variation is partly explained by
different diagnostic criteria for CC and most studies esti-
mate that the prevalence of CC is approximately 15%. Esti-
mates of CC prevalence based on Rome II criteria are lower
than estimates based on self-reporting. Constipation is re-
ported more commonly in women (2–3:1 predominance), the
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Table 1.1: Levels of Evidence and Grading of Recommendations∗
Level I Evidence: RCTs with p < 0.05, adequate sample sizes and appropriate methodology
Level II Evidence: RCTs with p > 0.05, or inadequate sample sizes and/or inappropriate methodology
Level III Evidence: Non-randomized trials with contemporaneous controls
Level IV Evidence: Non-randomized trials with historical controls
Level V Evidence: Case series
Grade A Recommendations: Recommendations supported by two or more level I trials without conflicting evidence from other level
I trials
Grade B Recommendations: Recommendations based on evidence from a single level I trial OR recommendations based on evidence
from two or more level I trials with conflicting evidence from other level I trials OR supported by
evidence from two or more level II trials
Grade C Recommendations: Recommendations based on level III-V evidence
∗Modified from Cook D, Guyatt G, Laupacis A, Sackett D. Chest 1992;102:305S
elderly, non-whites, and individuals from lower socioeco-
nomic groups (Grade C recommendation).
Population-based studies report that the prevalence of CC
in North America varies from 2% to 27%, and most estimates
cluster around 15%. This wide range of estimates probably re-
flects differences in definitions of CC and in study ascertain-
ment techniques rather than true differences in prevalence.
There are no rigorously designed studies on the natural his-
tory of CC in North America. Ideal longitudinal studies would
report on the frequency, duration, and intensity of CC symp-
toms, frequency of care seeking, medication use, utilization
of diagnostic procedures and impact on quality of life. Task
Force members support and endorse the execution of properly
designed population-based studies about the natural history
of CC in North America.
DIAGNOSTIC APPROACH TO THE PATIENT WITH
SYMPTOMS OF CHRONIC CONSTIPATION (SEE
SECTION 2.5)
Among CC patients without alarm symptoms or signs, there
are inadequate data to make a recommendation about the
routine use of flexible sigmoidoscopy, colonoscopy, barium
enema, thyroid function tests, serum calcium, and other di-
agnostic tests (Grade C recommendation). Diagnostic stud-
ies are indicated in patients with alarm symptoms and signs
which may include hematochezia, weight loss ≥10 pounds,
family history of colon cancer or inflammatory bowel dis-
ease, anemia, positive fecal occult blood tests, as well as for
the acute onset of constipation in elderly persons (Grade C
recommendation). A careful history and physical examina-
tion should be performed in order to identify symptoms or
signs of organic disorders (e.g., hypothyroidism) that may
be associated with CC symptoms. Specific diagnostic testing
(e.g., thyroid function tests) may be performed in individual
patients with additional signs or symptoms of an organic dis-
order. Routine use of colon cancer screening tools is recom-
mended for all patients ≥50 years old (Grade C recommen-
dation). Based upon expert opinion, the routine approach
to a patient with symptoms of CC without alarm signs or
symptoms should be empiric treatment without performance
of diagnostic testing (Grade C recommendation).
If the pretest probability of an organic disorder (e.g., hy-
percalcemia) is similar in patients with CC symptoms and in
controls, then the routine use of diagnostic testing (e.g., serum
calcium) to exclude this disorder cannot be recommended.
There are, however, no well-designed studies that assess ei-
ther the pre-test probability of organic disorders or the utility
of routine diagnostic tests among patients with CC symptoms.
Available evidence suggests that the likelihood of identifying
organic disorders with colonoscopy is similar among patients
with CC symptoms and among age-matched, asymptomatic
controls. Therefore, the routine use of colonoscopy to ex-
clude organic disorders cannot be endorsed in patients with
CC symptoms. Task force members emphasize that individ-
ual physicians may use diagnostic tests for specific patients
if the patient’s history and physical examination suggest the
presence of an organic disorder associated with CC symp-
toms. In the absence of adequate data, Task Force members
concluded that the routine use of a battery of diagnostic tests
should be avoided in patients with CC symptoms and that
the initial approach to these patients should be empiric treat-
ment. Alarm symptoms or signs indicate a subgroup of pa-
tients in whom diagnostic tests are indicated. Given the lack
of well-designed studies, Task Force members support and
endorse the execution of properly designed studies on this
topic.
THERAPY OF CHRONIC CONSTIPATION: BULKING AGENTS
(SEE SECTION 2.6)
Psyllium (e.g., Metamucil, Konsyl) increases stool fre-
quency in patients with CC (Grade B recommendation). There
are insufficient data to make a recommendation about the effi-
cacy of calcium polycarbophil (e.g., Perdiem Fiber Therapy,
Fibercon ), methylcellulose (e.g., Citrucel ), and bran in
patients with CC (Grade B recommendation).
Bulking agents available in the United States include
psyllium, calcium polycarbophil, methylcellulose, and wheat
bran. Bulking agents are FDA-approved for the treatment of
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occasional constipation. All trials evaluating these therapies
demonstrate sub-optimal study design and meet few of the
Rome committee recommendations for appropriate design
of a treatment trial for a functional gastrointestinal disorder
(see Table 2.1.1). Most of these trials had very small sample
sizes, short study duration, and were completed before the
development of criteria for the performance of therapy trials
in patients with functional gastrointestinal disorders. Also,
only one poorly designed randomized control trial (RCT) is
available to assess the efficacy of multiple bulking agents for
the treatment of CC.
There are three placebo-controlled trials of psyllium in pa-
tients with CC, and all were of suboptimal design. Generally,
these trials demonstrate that stool frequency or stool con-
sistency are improved by psyllium compared with placebo.
There are no placebo-controlled trials examining calcium
polycarbophil in patients with CC. There is one poorly-
designed trial comparing calcium polycarbophil with psyl-
lium that examined 32 patients and did not demonstrate any
statistically significant difference in stool frequency or stool
consistency between the two groups. There are no placebo-
controlled trials of methylcellulose. There is one poorly-
designed trial of 59 patients in which methylcellulose was
compared with psyllium. Patients took medication for only
10 days in this trial and no statistically significant differences
were demonstrated in stool frequency or stool consistency.
There are three RCTs of wheat bran in patients with CC,
but only one is placebo-controlled. All of these trials were
poorly designed. The placebo-controlled trial did not demon-
strate a statistically significant difference in stool frequency
or consistency for bran versus placebo. The other two trials
compared wheat bran with either corn biscuit or corn bran
and also did not demonstrate significant improvement in stool
frequency or consistency.
Data on adverse events were reported for few trials. No
statistically significant differences in adverse events were
identified between any bulking agent and an active compara-
tor or placebo. Task Force members noted that large quan-
tities of psyllium may be associated with bloating, which
may be a bothersome event. Also, mechanical obstruction
of the esophagus and colon has been reported with bulking
agents, and anaphylactic reactions have been reported with
psyllium.
THERAPY OF CHRONIC CONSTIPATION: STOOL
SOFTENERS (SEE SECTION 2.7)
There are insufficient data to make a recommendation about
the efficacy of stool softeners in patients with CC (Grade B
recommendation). Stool softeners may be inferior to psyllium
for improvement in stool frequency (Grade B recommenda-
tion).
Stool softeners available in the United States include do-
cusate sodium (e.g., Colace) and docusate calcium (e.g.,
Surfak). Stool softeners are FDA-approved for the treat-
ment of occasional constipation. There are four RCTs that
compare stool softeners with active comparators or placebo
in patients with CC. Generally, these trials had small sam-
ple sizes, only treated patients for 4 weeks, and did not en-
roll a uniform population of patients. In the trial comparing
docusate sodium (Colace) with psyllium, stool frequency
was significantly increased by week two with psyllium com-
pared with docusate sodium. One placebo-controlled trial
showed no difference in stool frequency or stool consistency
among patients taking stool softeners or placebo, but a sec-
ond placebo-controlled trial demonstrated a significant im-
provement in stool frequency for stool softeners compared
with placebo. Given the small sample sizes and conflicting
results in placebo-controlled trials, Task Force members felt
that there were insufficient data to make a recommendation
about the efficacy of stool softeners. The general consensus
of Task Force members was that stool softeners had minimal,
if any, effect to improve symptoms of CC. No data on adverse
events were provided in these trials.
THERAPY OF CHRONIC CONSTIPATION: OSMOTIC
LAXATIVES (SEE SECTION 2.8)
Polyethylene glycol (PEG) is effective at improving stool fre-
quency and stool consistency in patients with CC (Grade A
recommendation). Lactulose is effective at improving stool
frequency and stool consistency in patients with CC (Grade
A recommendation). There are insufficient data to make a
recommendation about the effectiveness of milk of magnesia
(MOM) in patients with CC (Grade B recommendation).
Osmotic laxatives are FDA-approved for treatment of occa-
sional constipation. There are five placebo-controlled RCTs
of PEG in patients with CC, and four of these RCTs demon-
strate medium-high quality for study design. There are two
RCTs that compared PEG with lactulose. All of these trials
demonstrated that PEG improves stool frequency and stool
consistency among patients with CC. There are three placebo-
controlled RCTs that examined the effectiveness of lactulose
in patients with CC, and two of these RCTs demonstrate
medium-high quality for study design. These trials demon-
strated that lactulose is more effective than placebo at im-
proving stool consistency and stool frequency. Only one study
reported adverse events, noting that lactulose-using patients
suffered more abdominal discomfort than did placebo-using
patients. There was only one RCT that assessed the effective-
ness of milk of magnesia (MOM) for patients with CC. This
crossover trial compared MOM with “laxamucil” and was a
low quality study that was difficult to interpret because of
multiple crossover periods. Therefore, Task Force members
felt that there were insufficient data to make a recommenda-
tion about the effectiveness of MOM for patients with CC.
Data on adverse events were not adequately reported
for most trials. Multiple electrolyte abnormalities (e.g.,
hypermagnesemia, hyperphosphatemia, hypercalcemia, hy-
ponatremia, hypokalemia), hypovolemia, and diarrhea have
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been reported with these agents, although the precise inci-
dence of these adverse events is unclear. Per FDA-approved
prescribing information, high doses of PEG may produce
diarrhea and excessive stool frequency, especially in el-
derly nursing home patients, and nausea, abdominal bloating,
cramping and flatulence may occur.
THERAPY OF CHRONIC CONSTIPATION: STIMULANT
LAXATIVES (SEE SECTION 2.9)
There are insufficient data to make a recommendation about
the effectiveness of stimulant laxatives in patients with CC
(Grade B recommendation).
Senna (e.g., Senokot, Ex-lax) or bisacodyl (e.g., Dul-
colax, Correctol, Carter’s Pills) is the active ingredient
of most stimulant laxatives available in the United States.
Stimulant laxatives are FDA-approved for the treatment of
occasional constipation. There are four RCTs that assess the
efficacy of stimulant laxatives in patients with CC. None of
these RCTs were placebo-controlled, and all of these RCTs
demonstrate low quality study design. None of these trials
demonstrated that stimulant laxatives were better than other
treatments for constipation, although stimulant laxatives were
less effective than lactulose in one study. Among trials that
reported adverse events, there was no significant difference in
adverse events between stimulant laxatives and other treat-
ments for constipation. Abdominal discomfort, electrolyte
imbalances, allergic reactions and hepatotoxicity have been
reported with these agents. Given the poor quality of study
design, lack of placebo-controlled trials, and inconclusive
results, Task Force members felt there were insufficient data
to make a recommendation about the efficacy of stimulant
laxatives for the management of CC, but that available data
suggest minimal benefit with these products.
THERAPY OF CHRONIC CONSTIPATION: TEGASEROD (SEE
SECTION 2.10)
Tegaserod is effective at in improving the frequency of com-
plete spontaneous bowel movements, straining, stool fre-
quency, and stool consistency in patients with CC (Grade
A recommendation).
Tegaserod is FDA-approved for treatment of CC in men and
women younger than 65 years of age. There are two large,
well-designed RCTs that compare tegaserod with placebo for
the management of CC. Each of these trials enrolled more
than 1,000 patients, was 12 weeks in duration, and demon-
strated high quality study design. Each trial demonstrated that
patients younger than 65 years old experienced significant
improvement in frequency of complete spontaneous bowel
movements, total spontaneous bowel movements, straining
and global satisfaction with bowel habits with tegaserod com-
pared with placebo. Diarrhea (6.6% vs 3.0%) occurred signif-
icantly more often among tegaserod-using patients compared
with placebo-using patients, although the diarrhea usually
was mild and transient with less than 1% of patients discon-
tinuing tegaserod because of diarrhea.
THERAPY OF CHRONIC CONSTIPATION: HERBAL
SUPPLEMENTS, ALTERNATIVE TREATMENTS,
LUBRICANTS, AND COMBINATION LAXATIVES (SEE
SECTION 2.11)
There are insufficient data to make a recommendation about
the effectiveness of herbal supplements, alternative treat-
ments, lubricants, or combination laxatives in patients with
CC (Grade C recommendation).
There are no published RCTs examining the efficacy of
herbal supplements (e.g., aloe) available in the United States
in patients with CC. There are no published RCTs on the
efficacy of lubricants (e.g., mineral oil) in adult patients
with CC, although there are RCTs examining mineral oil
in pediatric patients with CC and these trials indicate that
mineral oil is more effective than senna-based laxatives and
less effective than osmotic laxatives at improving stool fre-
quency and stool consistency. There are no published RCTs
of combination laxatives (e.g., psyllium plus senna) avail-
able in the United States in patients with CC. There are
no published placebo-controlled or sham-controlled random-
ized trials of biofeedback for the management of patients
with CC, although uncontrolled trials indicate that biofeed-
back techniques improve stool frequency compared with
baseline.
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2.1 Methods
Evidence-based guidelines should have:
(a) a transparent link between the evidence and the recom-
mendations;
(b) explicit criteria for inclusion of studies to serve as the
evidence;
(c) comprehensive searching of the literature for relevant
studies;
(d) a standardized and explicit system for grading the quality
of study design;
(e) a standardized and explicit system for grading recom-
mendations; and,
(f) recommendations that acknowledge the magnitude of
the treatment benefit, the adverse events associated with
the treatment, and individual patient preferences that
may guide the application of guideline recommendations
(1–3).
In order to fulfill these requirements, Task Force members
followed the techniques used to produce a previous Ameri-
can College of Gastroenterology evidence-based monograph
(4). Each section of the systematic review has been num-
bered to provide a link between the evidence and the rec-
ommendations. Standard techniques for literature searching
and study selection were utilized for each section of this doc-
ument (5, 6). Data about study methodology and study re-
sults were extracted onto standard forms and summaries of
data are presented in tables and graphs to insure that the
quality of study design was defined and that the magnitude
of treatment was quantified. A commonly used system for
grading recommendations in evidence-based guidelines (7)
was adapted for this document (see Section 2.2) and insured
that an explicit and transparent process was used to make
recommendations based upon the strength of the evidence.
Adverse events and individual patient preferences may af-
fect the application of these recommendations. Therefore,
adverse events have been assessed, relative contraindications
to specific treatments have been described, and Task Force
members contributed their expert advice based upon their
clinical experience.
Literature Search
In order to identify Chronic Constipation (CC) Ther-
apy Trials, the following literature search techniques were
employed. Separate PUBMED and MEDLINE searches
of English language articles from 1966–2003 were per-
formed with different combinations of the following search
terms: “constipation,” “laxatives, stimulant,” “laxatives, os-
motic,” “laxatives, irritant,” “laxatives, bulk,” “fecal soft-
eners,” “sorbitol,” “lactulose,” “milk of magnesia,” “mag-
nesium sulphate,” “bisacodyl,” “calcium polycarbophil,”
“polyethylene glycol,” “danthron,” “cascara,” “ispaghula,
“bran,” “celandin,” “docusate,” “poloxalkol,” “mineral oil,”
“glycerine,” “psyllium,” “methylcellulose,” “senna,” and
“tegaserod.” Exploded terms were reviewed, and where ap-
propriate, the search was expanded to include them. Manual
searches of reference lists from relevant articles also were
performed to identify additional studies that may have been
missed during the computer-assisted search.
In order to identify relevant studies about the Epidemi-
ology of CC and the Diagnostic Approach to Patients with
CC Symptoms, the following literature search techniques
were employed. For Epidemiology of CC, only English lan-
guage articles published in full manuscript form were consid-
ered. A search of the MEDLINE database from 1966–2003
was performed using the exploded (exp) MESH terms: exp
constipation AND (exp incidence OR exp prevalence OR
exp prognosis OR exp natural history OR exp epidemiol-
ogy OR exp quality of life). For EMBASE, a search from
1998–2002 was performed and modified to include only ar-
ticles that mentioned constipation in the title: constipation.ti
AND (exp incidence OR exp prevalence OR exp prognosis
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OR exp natural history OR exp epidemiology OR exp qual-
ity of life). The Current Contents database from Week 1,
2002 to Week 6, 2003 was searched with the terms consti-
pation.mp AND (incidence.mp OR prevalence.mp OR prog-
nosis.mp OR natural history.mp OR epidemiology.mp OR
quality of life.mp). Manual searches of reference lists from
potentially relevant articles also were performed to identify
any additional studies that might have been missed during the
computer-assisted search. For Diagnostic Approach to the Pa-
tient with CC Symptoms, a bibliographic database search of
MEDLINE from 1966 was performed. The search terms used
included “constipation,” “colonic diseases,” “Rome criteria,”
“colonoscopy,” “barium enema,” “defecation,” and various
systemic or local disorders that cause constipation such as
diabetes or colon cancer. Only human studies were consid-
ered. Bibliographies from all potentially relevant articles were
searched manually.
A medical education and research company (EBMed, LLC,
Anaheim Hills, CA) assisted the Task Force with literature
searches, application of study selection criteria, data extrac-
tion and analysis, and assessment of methodologic quality of
individual trials.
Study Selection Criteria
The titles and abstracts of all citations identified by the lit-
erature searches were reviewed. Potentially relevant studies
were retrieved, and the selection criteria were applied. Since a
North American perspective was used, only treatments avail-
able in the United States were examined and only epidemi-
ologic studies from North American populations were re-
viewed. For CC therapy trials, the selection criteria were: (a)
RCT; (b) population of adult patients with CC; (c) compar-
ison of CC therapy versus placebo or control therapy; (d)
evaluation of relief of CC symptoms; (e) results published
in English in full manuscript form (or adequate data avail-
able after written communication with investigators); and,
(f) therapy available in the United States. For Epidemiol-
ogy of CC studies, the selection criteria were: (a) studies of
population-based samples of CC patients in North America;
(b) population of adult patients (inclusion of pediatric patients
within an adult study population was allowed); (c) results re-
ported on prevalence, incidence, quality of life, or natural
history of CC; (d) results published in full manuscript form;
and (e) English language only. Case definition for constipa-
tion in these epidemiologic trials included patient self-report,
physician or ICD-9 diagnosis, consensus criteria from Rome
I or Rome II. For trials about the Diagnostic Approach to
the Patient with CC Symptoms, study inclusion criteria were:
(1) population of patients with CC symptoms (note: the def-
inition of constipation is extremely variable or inadequately
described in most studies and no single symptom was used
to define this condition; therefore, we included any study that
stated patients had CC symptoms.); (2) performance of diag-
nostic tests to diagnose organic disorders responsible for CC
symptoms; including complete blood cell count, biochemical
laboratory tests, colonoscopy, flexible sigmoidoscopy, bar-
ium enema, and plain abdominal radiography; (3) prevalence
of organic disorders responsible for CC symptoms or number
of patients with abnormalities on physiologic testing.
Data Extraction and Analysis
For CC therapy trials, data about study methodology and
study results were abstracted onto standard forms for the per-
formance of systematic reviews. Data were extracted about:
(a) study population; (b) intervention: dosage and schedule of
treatment versus placebo or control therapy; (c) study dura-
tion; and (d) proportion of patients achieving improvement in
global CC symptoms, stool frequency, stool consistency, and
adverse events. The Rome committee recommended study
design techniques to minimize bias in trials of functional GI
disorders (8) (Table 2.1.1). Data about the use of these tech-
niques were extracted. We also used a single grading system
that has been validated for appropriate study design of ther-
apy trials examined in a systematic review or meta-analysis
(9) (Table 2.1.2). Data about the use of proper randomiza-
tion, blinding and follow-up were extracted from each study
and summarized in tabular form. Because of wide variation
in study design, study endpoints, and dosages of study med-
ication, however, no attempt was made to combine results
into meta-analyses. Based on Rome Committee recommen-
dations (8), global improvement in symptoms is the ideal
endpoint for these trials because this endpoint encompasses
improvement in the multiple symptoms (e.g., straining, sense
of incomplete evacuation, bloating, etc.) of CC. Because few
trials evaluated this endpoint, however, Task Force members
agreed to expand the endpoints to include stool frequency and
stool consistency. Results of individual RCTs are presented in
tabular form. When individual RCTs reported numerical re-
sults, these results were included in the tables. When individ-
ual RCTs provided graphs or declarative statements without
numerical results, then declarative statements were included
Table 2.1.1. Qualitative Assessment of Study Methodology Scale∗#
1. Rome criteria to identify patients with chronic constipation
2. Randomization
3. Parallel study design (i.e., no crossover studies)
4. Double-blinding
5. Complete follow-up of patients
6. No placebo run-in
7. Baseline observation of patients to assess symptoms
8. Treatment duration of 8–12 wks or longer
9. Follow-up after treatment to assess symptoms
10. Compliance with the treatment is measured
11. Sample size calculation is provided and adequate sample size
enrolled
12. Primary outcome of the trial is improvement in global CC
symptoms
13. Primary outcome is based on patient assessment
14. Validated scale used to measure improvement in CC symptoms.
∗Data from van Zanten SJO, Talley NJ, Bytzer P, et al. Design of treatment trials for
functional gastrointestinal disorders. Gut 1999;45 (Suppl II):II69–77.
#The members of the Committee on Design of Treatment Trials for Functional
Gastrointestinal Disorders of the Rome II committee also noted additional recommen-
dations for the design of clinical trials, including an a priori -defined study endpoint
and definition of patient setting (primary care vs tertiary care). Published reports,
however, rarely provide adequate information to assess the use of these additional
techniques in the conduct of treatment trials. Therefore, these additional techniques
were not included in the scale.
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in the tables. Due to the lack of RCTs, no data about the
management of pelvic floor disorders are included.
For Epidemiology of CC studies, data about study method-
ology and study results also were abstracted onto standard
forms. Data were abstracted about: (a) symptom-based defi-
nition of CC (e.g., patient self-report or Rome Criteria); (b)
sample size and case ascertainment technique to identify CC
patients; (c) prevalence, incidence, prevalence of CC sub-
groups, gender distribution, race distribution, socioeconomic
distribution, diseases associated with CC, and mean age of
onset of symptoms; and (d) disease activity (e.g., prevalence
of CC over time and frequency of CC flares within a speci-
fied period of time) and/or quality of life data. For trials about
the Diagnostic Approach to the Patient with CC Symptoms,
data were abstracted about: (a) symptom-based criteria used
to identify CC patients; (b) diagnostic evaluation performed;
(c) prevalence of confirmed organic GI disease, resulting in
an alternative diagnosis to explain CC symptoms or preva-
lence of abnormal results on diagnostic tests.
2.2 Levels of Evidence and Grading
of Recommendations
Quantitative Assessment of Study Methodology
Previous reviews and epidemiologic studies (10–12) have
established criteria that minimize bias in trials about ther-
apy, including the use of randomization, concealed alloca-
tion, double-blinding, and complete patient follow-up. A sin-
gle grading system has been validated for appropriate study
design of therapy trials examined in a systematic review or
meta-analysis (9) (Table 2.1.2). In order to assess the strength
of individual studies about CC therapies, data about the use
of these techniques were extracted, summarized in a quantita-
tive scale, and presented in tabular form. This scale estimates
the rigor of an individual trial: a trial with a low quality score
may be more likely to produce inaccurate or biased results
and a trial with a high quality score may be more likely to
produce accurate and unbiased results (8–10). Additionally,
the Rome committees described the preferred design of treat-
ment trials for functional gastrointestinal disorders (8) (Table
2.1.1). Data about use of these additional Rome committee
criteria for appropriate design of treatment trials also were
extracted and are presented in descriptive form.
Table 2.1.2. Jadad Criteria-Validated Scale to Assess Quality of Study Design for Treatment Trials in a Systematic Review or Meta-Analysis
Randomization
+2 Randomized with Concealed Allocation and Appropriate Description of Randomization Process
+1 Trial described as randomized, but no further information provided
0 Not randomized
Blinding
+2 Double-blind with appropriate description of techniques used to insure double-blinding (e.g., double-dummy technique)
+1 Trial described as double-blind, but no further information provided
0 Not blinded
Complete Follow-Up
+1 Statement about number of patients lost to follow-up and reason for loss to follow-up provided
0 No statement about number of patients lost to follow-up or reason for loss to follow-up provided
Jadad A, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized controlled trials: Is blinding necessary? Controlled Clin Trials 1996;17:1–12.
Scores of 4–5 are consistent with a well-designed RCT, while scores of 1–2 are consistent with a poorly-designed trial.
No standard criteria are available to rate the quality of
study design of epidemiologic studies in a systematic review.
Population-based studies may be preferable to studies of re-
ferral populations because referral populations may provide
inflated estimates of the prevalence and incidence of a dis-
order. Therefore, epidemiologic studies in this review are
limited to population-based studies.
Levels of Evidence
Levels of Evidence have been defined previously (see Table
1.2). Level I evidence represents high quality RCTs. These
RCTs have few limitations in their study design, which should
minimize Type I errors. Thus, if a RCT shows a significant
difference between treatment and placebo, then this finding
probably did not result from biased study design. These RCTs
also have adequate power to minimize Type II errors. Thus, if
a RCT does not show a significant difference between treat-
ment and placebo, then this finding probably did not occur
because of an inadequate sample size of patients. Level II
evidence represents intermediate quality RCTs. These RCTs
have important limitations in their study design, which could
produce a Type I error. Intermediate quality RCTs also may
be susceptible to Type II errors because of inadequate sam-
ple size. Level III–V evidence comes from non-randomized
trials or case series. These are observational studies that are
prone to multiple biases that produce Type I errors. For this
review, Level III–V evidence was not used to make recom-
mendations about CC therapies. Level III–V evidence was
used only to make recommendations about the Diagnostic
Approach to the Patient with CC Symptoms or about Epi-
demiology of CC because data on these topics are available
only from observational studies.
Grading of Recommendations
Recommendations are listed as Grade A, Grade B, or Grade
C (see Table 1.2). Grade A recommendations are supported
by the strongest (Level I) evidence. Task Force members
strongly believe that these recommendations are accurate
based upon the evidence. Grade B recommendations are sup-
ported by intermediate quality (Level II) evidence. Task Force
members believe that Grade B recommendations may have
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important limitations because of the intermediate quality of
the evidence. These recommendations may change in the fu-
ture if high quality (Level I) evidence becomes available.
Grade C recommendations are supported by observational
studies (Level III–V evidence). The strength of evidence be-
hind these recommendations is limited, and Grade C recom-
mendations are provided only because they represent the best
evidence about the Epidemiology of CC and the Diagnostic
Approach to Patients with CC Symptoms.
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2.3 Symptom-based Criteria for Diagnosing Chronic
Constipation and Threshold to Treat Chronic Constipation
Constipation is a symptom-based disorder defined as unsatis-
factory defecation and is characterized by infrequent stools,
difficult stool passage, or both. Difficult stool passage in-
cludes straining, a sense of difficulty passing stool, incom-
plete evacuation, hard/lumpy stools, prolonged time to stool,
or need for manual maneuvers to pass stool (Grade C Recom-
mendation). CC is defined as the presence of these symptoms
for at least 3 months (Grade C recommendation). Available
evidence indicates that self-reported constipation is associ-
ated with decreased quality of life (Grade C recommenda-
tion). Treatment of patients with CC is indicated when the
symptoms diminish quality of life. (Grade C recommenda-
tion).
CC may be associated with dysfunction of intestinal motil-
ity, visceral sensitivity, ano-rectal musculature and the enteric
nervous system, but no structural, biochemical, or physio-
logical abnormalities are demonstrated consistently in CC
patients; therefore, the definition of CC is symptom-based.
Symptoms of CC include decreased stool frequency, difficult
stool passage or both. Symptoms of difficult stool passage
include straining, a sense of difficulty passing stool or of in-
complete evacuation, hard/lumpy stools, prolonged time to
stool, and need for manual maneuvers to pass stool (1).
Symptom-based criteria for the diagnosis of CC have been
developed by functional bowel disorder experts to facilitate
the diagnosis of CC (2). These symptom-based criteria, also
known as the Rome criteria (Table 2.3.1), are used to identify
CC patients for research studies, but they are probably too
detailed for use in the primary care setting. In fact, few pri-
mary care physicians use Rome criteria to identify patients
with irritable bowel syndrome (IBS) (3). Furthermore, both
the Rome criteria (2) and physicians (4) emphasize that CC is
defined by less than 3 bowel movements per week, although
many patients who report CC pass ≥3 bowel movements per
week (4). These patients report CC because of difficult stool
passage (e.g., straining, sense of incomplete evacuation, etc.).
Given the uncertain clinical utility of Rome criteria for iden-
tification of patients with CC, Task Force members suggest
that physicians use a broad definition of CC: “unsatisfactory
defecation characterized by infrequent stools, difficult stool
passage or both. Difficult stool passage includes straining,
a sense of difficulty passing stool, incomplete evacuation,
hard/lumpy stools, prolonged time to stool, or need for man-
ual maneuvers to pass stool.” In order to define constipation
as a chronic disorder, Task Force members felt that some
combination of these symptoms should be present for at least
three of the previous 12 months (5).
Task Force members noted that the symptom-based criteria
for CC and IBS might overlap. Task Force members there-
fore emphasized that the presence of clinically important ab-
dominal discomfort associated with constipation symptoms
defines IBS with constipation. Most patients with CC may
report minimal abdominal bloating or discomfort associated
with their other CC symptoms, creating a spectrum between
CC and IBS (Fig. 2.3.1). Indeed, in some patients it may be
difficult, if not impossible, to differentiate CC and IBS accu-
rately and reliably.
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Table 2.3.1. Rome Criteria for the Diagnosis of Chronic Functional Constipation (2)
1. Two or more of the following symptoms for at least 12 wks (which need not be consecutive wks) in the preceding 12 months
- Straining during >25% of bowel movements
- Lumpy or hard stools for >25% of bowel movements
- Sensation of incomplete evacuation for >25% of bowel movements
- Sensation of anorectal blockage for >25% of bowel movements
- Manual maneuvers to facilitate >25% of bowel movements (e.g., digital evacuation or support of pelvic floor)
- <3 bowel movements per week.
2. Loose stools are not present.
3. Insufficient criteria for the diagnosis of irritable bowel syndrome
4. No organic disorder responsible for chronic constipation symptoms is present
Several physiologic sub-types of CC have been described,
including colonic inertia (e.g., decreased colonic transit),
outlet delay constipation (e.g., pelvic floor dyssnergia), and
functional constipation without delays in colonic transit or
outlet delay. There are no symptom-based criteria, however,
that effectively identify the different sub-types of CC and
these sub-types may coexist in individual patients.
In one study, CC symptoms were associated with a signifi-
cant decrease in quality of life among CC patients who sought
medical care for their symptoms (6). This study also demon-
strated decreased mental and physical sub-scores on the SF-
36 questionnaire in a population-based sample of Canadians
with constipation when these patients were compared with
control patients without any functional GI disorder. Based on
these data, the Task Force members stated that self-reported
CC is associated with a clinically important decrease in qual-
ity of life.
Although limited evidence indicates that CC dimin-
ishes quality of life, there are no data available to guide
recommendations about the threshold to treat CC. There-
fore, Task Force members developed an expert-based rec-
ommendation: treatment should be initiated when the pa-
tient and physician feel that CC symptoms are diminish-
ing the quality of life of the patient. Treatment may in-
clude lifestyle modification (e.g., increases in daily fiber,
increased water consumption, increased exercise) and/or
drug therapy, although lifestyle modifications have not been
proven effective at increasing stool frequency or stool con-
sistency. Task force members also noted that treatment may
be appropriate if constipation symptoms potentially could
worsen another disorder or condition (e.g., a patient who re-
cently has had a myocardial infarction or a demented nurs-
ing home patient with a history of constipation and fecal
impaction.)
Figure 2.3.1. Spectrum of chronic constipation and irritable bowel syndrome (IBS) with constipation.
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2.4 Epidemiology of Chronic Constipation in
North America
Estimates of the prevalence of CC in North America vary
between 2% and 27%. This variation is partly explained
by different diagnostic criteria for CC. Most studies esti-
mate that the prevalence of CC is approximately 15%. Esti-
mates of CC prevalence based on Rome II criteria are lower
than estimates based on self-reporting. Constipation is more
commonly reported in women (2–3:1 predominance), the el-
derly, non-whites, and individuals from lower socioeconomic
groups (Grade C recommendation).
Understanding the epidemiology and natural history of CC
facilitates physician and patient education. In this portion of
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Table 2.4.1. Prevalence of Constipation in Representative Population Samples in North America
Study Population Year Ascertain N (% response) Case Criteria Prevalence per 100
Hammon ACS 1964 Mail survey 890,394 (NR) Self-report 27.1
Sandler NHANES I 1971–5 FTF 15,014 (NR) Self-report 12.8
Everhart NHANES I 1971–5 FTF 11,024 (74.4) Self-report 15.8
Johanson NHIS 1983–7 FTF NR (NR) Self-report 1.9
Harari NHIS 1989 FTF 42,375 (NR) Self-report 3.4
Talley Olmsted whites 1991 Mail survey 835 (82) (Strain AND Hard) OR <3/wk 17.4†
Talley Olmsted whites 1993 Mail survey 690 (83) Self-report 5.0
∗
Rome I FC 19.2
∗
Rome I OD 11.0
∗
Drossman Household 1993 Mail survey 5,430 (66) Rome I FC 3.6
Rome I Dyschezia 13.8
Stewart US EPOC 1997 Phone survey 10,018 (53.6) Rome II, FC or OD or IBS-C 14.7
Pare Canada 2000 Mail survey 1,149 (57) Self-report 27.2
Rome I 16.7
Rome II 14.9
NR = not reported; FTF = face-to-face interview; FC = functional constipation; OD = obstructive defecation.
†Age- and gender-adjusted prevalence.
Age-adjusted prevalence NHANES: National Health and Nutrition Examination Survey; NHIS: National Health Interview Survey; US EPOC: United States epidemiology of
constipation; ACS: American Cancer Society volunteers; Reproduced from Higgins P, Johanson J. Epidemiology of chronic constipation: A systematic review. Am J Gastroenterol
2004;99:750–9.
the monograph, our objectives were to review the epidemiol-
ogy literature systematically about: (a) the prevalence of CC
in North America; (b) the age, gender, and socioeconomic
status of patients with CC in North America; and, (c) to char-
acterize the natural history of constipation (1).
Ten population-based North American studies (2–11)
quantify the prevalence of CC or provide other epidemio-
logic data about CC in North America. Literature search
techniques, study selection criteria, and data analysis are out-
lined in Section 2.1. In these studies, the diagnosis of CC
was made based on self-reports, Rome I or Rome II criteria
(Table 2.4.1).
Figure 2.4.1. Overlap between functional GI disorders.
The reported prevalence of CC varied between 2% and 27%
(2–11), although most studies estimated prevalence at 10–15
% (Table 2.4.1). Differences in the reported prevalence of
CC probably reflect differences in study design (e.g., mailed
surveys versus face-to-face interviews) or variation in the
symptom-based definitions of CC (e.g., Rome I versus Rome
II criteria versus different criteria for self-reports of CC).
Multiple factors were associated with CC. Specifically,
women report CC approximately twice as often as do men.
Task Force members noted that the greater prevalence of CC
in women may arise from the increased prevalence of pelvic
floor dyssynergia in women. Also, low socioeconomic group-
ing (e.g., annual income less than $20,000), age older than
65 years, and non-White race have been associated with an in-
creased prevalence of CC (1). Task Force members noted that
the increasing prevalence of CC with advancing age might
reflect the increased prevalence of secondary causes of con-
stipation (e.g., an increased prevalence of Parkinson’s disease
or diabetes mellitus). There are no definitive data to suggest
that the colonic musculature atrophies with advancing age,
and, therefore, new onset constipation symptoms in the el-
derly should be investigated. Task Force members also noted
that the increased prevalence of CC in non-White individu-
als in North America may reflect dietary issues and that this
is another area for further research. Finally, the association
between CC and low socioeconomic grouping is the exact op-
posite of IBS, which is associated with higher socioeconomic
grouping (12).
CC is frequently associated with other gastrointestinal
motility and sensory disorders, including functional dyspep-
sia, functional heartburn, and GERD (13, 14) (Fig. 2.4.1). In
fact, 29% of GERD patients also report CC (14). Given this
overlap, Task Force members hypothesized that there may be
common pathophysiologic mechanisms (13) for these disor-
ders and that this too is another area for further research.
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The literature search did not reveal any North American
population-based studies about the natural history of CC. One
study (15) surveyed the population in Olmsted County, MN,
on two separate occasions over 12–20 months. This study
indicated that the prevalence of chronic constipation is 17.4%
(95% CI: 14.8–20.0%), and 89% of CC patients still had
similar symptoms during repeat survey 12–20 months later.
The incidence of CC symptoms is approximately four per
100 person-years of follow-up.
Overall, Task Force members noted that the quality and
quantity of epidemiologic studies about CC are limited. Ap-
propriately designed studies about the natural history of CC
should be completed. Task Force members proposed that ad-
ditional studies should be performed about the impact of CC
on quality of life. Comprehensive epidemiologic studies may
determine why certain risk factors, including race, gender, so-
cioeconomic status, and age, are associated with an increased
prevalence of CC. Such studies may also identify symptoms
that better define sub-types of CC.
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2.5 Diagnostic Approach to the Patient with
Chronic Constipation Symptoms
Among CC patients without alarm symptoms or signs, there
are inadequate data to make a recommendation about the
routine use of flexible sigmoidoscopy, colonoscopy, barium
enema, thyroid function tests, serum calcium, and other di-
agnostic tests (Grade C recommendation). Diagnostic stud-
ies are indicated in patients with alarm symptoms and signs
which may include hematochezia, weight loss ≥10 pounds,
family history of colon cancer or inflammatory bowel dis-
ease, anemia, positive fecal occult blood tests, and the acute
onset of constipation in elderly persons (Grade C recommen-
dation). A careful history and physical examination should
be performed in order to identify symptoms or signs of or-
ganic disorders that may be associated with CC symptoms
(e.g., hypothyroidism). Specific diagnostic testing (e.g., thy-
roid function tests) may be performed in individual patients
with additional signs or symptoms of an organic disorder.
Routine use of colon cancer screening tools is recommended
for all patients ≥ 50 yr (Grade C recommendation). Based
upon expert opinion, the routine approach to a patient with
symptoms of CC without alarm signs or symptoms should be
empiric treatment without performance of diagnostic testing.
(Grade C recommendation).
The symptoms of CC may be due to dysfunction of in-
testinal motility, visceral sensitivity, ano-rectal musculature,
or the enteric nervous system. Also, CC symptoms may be
secondary to an organic disorder, including metabolic disor-
ders (e.g., hypothyroidism), myopathies (e.g., amyloidosis),
neurologic disease (e.g., the Parkinson disease), or medica-
tions (e.g., opiates) (1). Numerous diagnostic tests, including
laboratory tests (e.g., complete blood count, thyroid func-
tion tests, serum calcium) and structural tests of the colon
(e.g., colonoscopy, flexible sigmoidoscopy, barium enema),
have been recommended to exclude secondary causes of CC
symptoms although “data do not exist to strictly evaluate and
define the tests that need to be done” (1).
If the pre-test probability of an organic disorder (e.g., hy-
percalcemia) is similar in patients with CC symptoms and in
control patients, then the routine use of additional diagnos-
tic testing for that disorder (e.g., serum calcium) cannot be
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Table 2.5.1. Specialized Diagnostic Testing in Patients with Chronic Constipation Symptoms (8, 9)
1. Colon Transit Studies. The patient swallows a capsule containing 24 radio-opaque markers. Over the following 5 days, the patient should
maintain a high fiber diet, but abstain from using laxatives, enemas, or medicines that affect bowel function. On Day 5, the patient
undergoes an abdominal plain film. If > 20% of the radio-opaque markers are retained in the colon, then slow-transit constipation is
confirmed.
2. Defecography. Thickened barium, which approximates the consistency of stool, is inserted into the rectum. The patient then sits on a
radiolucent commode. During evacuation of the barium, fluoroscopy is utilized to assess ano-rectal anatomy and structures, including
the ano-rectal angle, perineal descent, and any abnormalities. Pelvic floor dyssynergia is diagnosed by the observation of insufficient
descent of the perineum (< 1 cm) and less than a normal change in the anorectal angle (< 15 degrees). Rectoceles and intussusceptions
also may be diagnosed by this technique. Defecography is operator dependent and has poor reliability.
3. Anorectal manometry with balloon expulsion. Provides measurements of the internal and external anal sphincter pressure, relaxation of
the internal anal sphincter during rectal distention and straining, and rectal sensation to distention. Appropriate internal anal sphincter
relaxation excludes Hirschprung disease. This may be the screening test of choice for outlet obstruction.
recommended. In this portion of the monograph, our objec-
tives were to review the literature systematically to determine:
(a) the pre-test probability of underlying organic disorders
among patients who present with CC symptoms; and (b) to as-
sess the utility of diagnostic tests (e.g., CBC, serum calcium,
thyroid function tests, flexible sigmoidoscopy, colonoscopy,
barium enema) to diagnose organic disorders producing CC
symptoms. Literature search techniques, study selection cri-
teria, and data analysis are outlined in Section 2.1.
No appropriately designed studies estimate the pre-test
probability of organic disorders among patients with CC
symptoms or assess the utility of testing to diagnose organic
disorders producing CC symptoms. Appropriately designed
studies perform a prospective evaluation of a diagnostic test
in a consecutive sample of patients with pre-defined symp-
tom criteria. If possible, the diagnosis of an organic disorder
is confirmed with a “gold standard” diagnostic test (2–3). In
order to define the current state of the literature, Task Force
members reviewed retrospective studies of non-consecutive
patients with CC symptoms.
No studies examined the utility of laboratory testing (e.g.,
CBC, serum calcium, thyroid function tests) in the evalua-
tion of patients with CC symptoms. A retrospective study
of patients with CC symptoms who underwent colonoscopy
(N = 358) or flexible sigmoidoscopy (N = 205) revealed a
1.6% prevalence of colon cancer (including one malignant
polyp) and a 14.4% prevalence of adenoma (4). The authors
reported that no patient with colon cancer had constipation
as the sole indication for colonoscopy or flexible sigmoi-
doscopy. This study did not include controls to determine if
the prevalence of colorectal neoplasia in patients with CC
symptoms was similar to an appropriate population of con-
trol patients, although the authors suggested that the rates of
colon cancer and adenoma in their study were similar to prior
studies of screening colonoscopy in asymptomatic patients.
Based upon these data, Task Force members concluded that
the routine use of colonoscopy to exclude organic disorders
cannot be endorsed in patients with CC symptoms, although
the routine use of colonoscopy for colon cancer screening is
recommended for all patients ≥ 50 yr. This recommendation
is consistent with current recommendations from the Amer-
ican Society for Gastrointestinal Endoscopy (ASGE) (5).
Barium enemas were evaluated in a select group of 62
patients with CC symptoms prior to undergoing an anorec-
tal myectomy and no “organic lesions” or narrowed segments
were identified in any patient (6). Another study assessed 791
patients with positive findings on a barium enema, 22% of
whom had constipation (7). They reported that the frequency
of constipation was nearly identical among patients regard-
less of whether the barium enema was normal or abnormal
(ratio = 0.95).
Among patients with CC symptoms who do not respond to
conventional therapy, the diagnosis of slow transit constipa-
tion, pelvic floor dyssnergia, and other disorders of ano-rectal
musculature may be considered. Diagnosis of these disorders
is possible with specialized physiologic and radiologic test-
ing (Table 2.5.1); however, no appropriately designed studies
have been performed to determine the utility of routinely
performing these tests among patients with CC symptoms.
Ano-rectal manometry with balloon expulsion and defecog-
raphy facilitate diagnosis of outlet obstruction, Hirschprung
disease, and pelvic floor dyssynergia. These specialized phys-
iologic and radiologic tests are recommended for patients
whose symptoms have not responded to conventional thera-
pies and who complain of excessive straining or the need to
use digital manipulation to evacuate stool (8, 9). Colon tran-
sit studies, which diagnose slow transit constipation, may be
utilized in patients with severe constipation unresponsive to
multiple therapies or when surgical treatment of severe, re-
fractory constipation is being considered (8).
Based upon their clinical experience and available evi-
dence, Task Force members did not endorse the routine use of
a battery of diagnostic tests among patients with CC symp-
toms. They proposed that the initial approach to patients with
CC symptoms should be empiric therapy. Task Force mem-
bers emphasized that a detailed history and physical exam-
ination are needed to identify disorders that may produce
CC symptoms. Physicians may selectively utilize specific di-
agnostic tests (e.g., thyroid function tests) if a patient’s his-
tory and physical examination suggest an organic disorder
(e.g., hypothyroidism) associated with CC symptoms. Alarm
symptoms or signs indicate a subset of patients in whom diag-
nostic tests are indicated (Table 2.5.2). Task Force members
acknowledged that there is inadequate evidence to make a
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Table 2.5.2. Alarm Symptoms/Signs in Patients with Chronic Con-
stipation
1. Hematochezia
2. Family history of colon cancer
3. Family history of inflammatory bowel disease
4. Anemia
5. Positive fecal occult blood test
6. Weight loss ≥ 10 pounds
7. Severe, persistent constipation that is unresponsive to treatment
8. New onset constipation in elderly patient without any evidence
of a possible primary cause of constipation
This table is not intended as an exhaustive list of all possible alarm symptoms/signs
that may indicate the need for additional diagnostic testing.
strong recommendation about the appropriate diagnostic ap-
proach to patients with CC symptoms, and they endorsed the
execution of properly designed studies about this topic.
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2.6 Effectiveness of Bulking Agents in the
Treatment of Chronic Constipation
Psyllium (e.g., Metamucil, Konsyl) increases stool fre-
quency in patients with CC. (Grade B recommendation).
There are insufficient data to make a recommendation about
the efficacy of calcium polycarbophil (e.g., Perdiem Fiber
Therapy, Fibercon), methylcellulose (e.g., Citrucel) and
bran in patients with CC (Grade B recommendation).
Among patients with CC, stools may be deficient in wa-
ter content. Bulking agents are organic polymers that re-
tain water in the stool. By adding water and additional solid
material to stool, these agents may improve CC symptoms.
Several of these agents (e.g., psyllium), undergo bacterial
fermentation in the colon thereby producing gas with resul-
tant bloating. Bulking agents available in the United States
include psyllium (Metamucil, Konsyl), calcium polycar-
bophil (Perdiem Fiber Therapy, Fibercon), methylcellu-
lose (Citrucel), and bran. Mechanical obstruction of the
esophagus and colon has been reported with bulking agents,
and anaphylactic reactions have been reported with psyllium
(1). Bulking agents are FDA-approved for the treatment of
occasional constipation.
Psyllium
Psyllium husk is the outer coat of the psyllium seed (known in
India as ispaghula seed) from the plant Plantago ovata. Five
RCTs were found (Table 2.6.1), three of which are placebo
controlled (2–4). Only one of these was of high quality (4),
and it was the only one lasting more than 4 wk. It included
only 22 patients and met only 5 of 14 Rome criteria. Two
trials compared psyllium with “active” agents, but neither
was of high quality (5, 6). The largest trials were low qual-
ity (3, 5, 6). In two of the three placebo-controlled trials,
psyllium resulted in greater stool frequency, better stool con-
sistency, and greater ease of defecation (3, 4). In the third
study, there was no significant increase in stool frequency, and
stool consistency and stool weights were not improved (2).
When compared with other laxatives, patients taking psyl-
lium noted a higher percentage of normal, well-formed stool
and fewer hard stools compared with baseline (5). The inci-
dences of soiling, diarrhea, and abdominal pain also were
reduced. Both psyllium and lactulose improved stool fre-
quency and consistency compared with baseline, but there
were no significant differences in magnitude of improvement
between the lactulose-using patients and psyllium-using pa-
tients (6). Overall, these trials display weak study design, in-
cluding small sample sizes, short study duration (≤14 days),
or both. Based on low-intermediate quality RCTs, psyllium
appears to improve stool frequency and consistency (Grade
B recommendation). There were no statistically significant
differences in side effects among psyllium, placebo, and lac-
tulose.
Calcium polycarbophil
Only one trial of calcium polycarbophil is available and it
is not placebo-controlled (7). This crossover study in 32
bed-ridden nursing home patients compared Fibercon with
psyllium, each taken for 3 wk. It had a quality score of 1.
There were no significant differences in stool frequency (7.2
stools/wk vs 7.22 stools/wk), stool consistency, and ease of
defecation. Because of the lack of data, it is not possible to
make any recommendation about calcium polycarbophil as
treatment for constipation. There was no reporting of ad-
verse events in this study, so the frequency of diarrhea or
other adverse events with calcium polycarbophil cannot be
determined.
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Table 2.6.1. Trial Characteristics: Psyllium
Outcomes Quality
Trial Study Type Treatment Dose Control N Duration Measured Score
2 (Cheskin) Crossover Psyllium
(Konsyl)
24 g/d Placebo 10 4 wks each arm SF, SC 3
Result: No significant difference in stool frequency/wk with psyllium compared with placebo (1.3 vs 0.8, respectively; p > 0.05). No
difference in stool weights or stool consistency.
3 (Fenn) Parallel Psyllium
(Regulan)
6.4 g sachets (3.6 g
psyllium t.i.d.)
Placebo 183 2 wks SF, SC 3
Result: The median number of formed stools/wk (9 vs 3), loose stools/wk (1 vs 0), and total stools/wk (14 vs 9) was significantly greater
with psyllium compared with placebo. A significant decrease in abdominal discomfort (87% vs 46%, respectively; p < 0.05) and
straining (89% vs 48%, respectively; p < 0.05) was observed.
4 (Ashraf) Parallel Psyllium 5 gm b.i.d. Placebo 22 8 wks after SF, SC, 4
(Metamucil) 22 4 wk placebo EOD
run-in
Result: Stool frequency/week (3.8 vs 2.9, respectively), stool consistency-Likert scale measurement (3.2 vs 3.8, respectively), and ease of
defecation-Likert scale measurement (2.0 vs 2.6, respectively) were significantly better with psyllium compared with placebo.
5 (Dettmar) Parallel Psyllium
(Fybogel)
3.5 g b.i.d. “Other
laxatives”
381 4 wks SF, SC 2
Result: Percentage of normal, well-formed stools and hard stools were significantly improved with psyllium compared with
“other laxatives.” Incidence of soiling, diarrhea, and abdominal pain was significantly lower with psyllium compared with placebo. No
interpretable numbers provided in study results.
6 (Rouse) Parallel Psyllium 3.5 g b.i.d. Lactulose 112 4 wks SF, SC, 2
(Fybogel) 30 mL/d SGA
Result: Psyllium and Lactulose improved stool frequency/wk (6.5 and 7.5) and stool consistency compared with baseline, but there were
no significant differences between psyllium and lactulose. Psyllium was more likely than lactulose to be considered unpalatable (15.7%
vs 4.2%, respectively; p < 0.05).
SF = stool frequency; SC = stool consistency; EOD = ease of defecation;
SGA = subjective global assessment of bowel habits.
Methylcellulose
Only one study of methylcellulose (Citrucel) is available
(8). This was a parallel design study in which 59 patients
took one of three doses of methylcellulose or psyllium for
only 10 days after a 1 week placebo run-in period. The qual-
ity score was only 2. There were no significant differences
in stool frequency, stool consistency or ease of defecation
among the treatments. Each one led to improvement com-
pared with the placebo run-in period. Because of the lack of
data, it is not possible to make any recommendation about
Table 2.6.2. Trial Characteristics: Bran
Outcomes Quality
Trial Study Type Treatment Dose Control N Duration Measured Score
9 (Badiali) Crossover Wheat Bran 6.6 g t.i.d. Placebo 24 4 wks each arm after 3 wks SF 4
Result: Wheat bran and placebo increased stool frequency/wk compared with baseline, but there were no significant differences
between treatments.
10 (Anderson) Parallel Corn Biscuit or Wheat Bran 10 g/day No Bran 40 2 wks after 2 wk SF, SC 1
Result: Corn biscuit and wheat bran increased stool frequency/wk and improved stool consistency compared with baseline.
Wheat bran significantly increased stool frequency/wk compared with no treatment (data not shown in study).
11 (Graham) Parallel Wheat Bran 10 g b.i.d. Corn Bran 10 2 wks SF, SGA 1
Result: Wheat bran significantly increased stool frequency/wk (data from figure not interpretable). Subjective Global Improvement
in bowel function, measured on a Likert scale, favored corn bran (5/5) over wheat bran (0.5).
SF = stool frequency; SC = stool consistency; SGA = subjective global assessment of bowel habits; Likert scale = 5-point or 7-point scale for assessing severity of specific
symptoms (e.g., straining)
methylcellulose as treatment for constipation. There was no
reporting of adverse events in this study.
Bran
Three RCTs were found (Table 2.6.2). One trial was placebo-
controlled and it had a quality score of 4, with 10 Rome
criteria met (9); however, it was a crossover design with only
24 patients and the duration on each arm was only 4 wk.
The other two studies were of very poor quality (10, 11) with
quality scores of 1.
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In the first study, stool frequency was significantly greater
with bran than with placebo if placebo was given first, but
not if bran was given first (9). This suggests a placebo run-in
effect. Both treatments increased stool frequency compared
with the 3-wk baseline period. Other symptoms were not
significantly different between bran and placebo. The other
two studies were of such low quality that their results are
impossible to interpret (10–11). Given the lack of data, it
is not possible to make any recommendation about bran as
treatment for constipation. There was no reporting of adverse
events.
Overall, studies of bulking agents were of sub-optimal de-
sign and only one study met as many as 10 Rome criteria for
appropriate design of a treatment trial for a functional gas-
trointestinal disorder (9). Most of the trials had very small
sample sizes, were of short duration, and were performed
before the advent of what are now the generally accepted cri-
teria for treatment trials in patients with functional disorders.
Data from two systematic reviews (12–13) provide conflict-
ing results. One systematic review (12) performed sub-group
analysis of bulking agent trials and concluded that bulking
agents were more effective than placebo at improving stool
frequency, while a more recent meta-analysis (13) combined
RCTs of multiple agents (e.g., stimulant laxatives, bulking
agents, and osmotic laxatives) and did not find evidence that
active agents were better than placebo in trials of 5–12 week
duration.
Data on adverse events were reported in only a few tri-
als but, where reported, revealed no statistically significant
differences in adverse events identified between the bulking
agent studied and the comparator. Nevertheless, bloating and
severe adverse events, including esophageal and colonic ob-
struction and anaphylactic reactions, have been reported with
bulking agents (1).
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2.7 Effectiveness of Stool Softeners in the
Treatment of Chronic Constipation
There are insufficient data to make a recommendation about
the efficacy of stool softeners in patients with CC (Grade B
recommendation). Stool softeners may be inferior to psyllium
for management of CC symptoms (Grade B recommendation).
“Stool softeners” are surface-acting agents, that function
primarily as detergents (i.e., they allow water to interact more
effectively with solid stool, thereby “softening” the stool).
Stool softeners available in the United States include do-
cusate sodium (Colace) and docusate calcium (Surfak).
Stool softeners are FDA-approved for the treatment of occa-
sional constipation.
There are four RCTs that compare stool softeners with
active comparators or placebo in patients with CC (1–4)
(Table 2.7). Three of these RCTs demonstrate high quality
study design (1, 2, 4), and one of these RCTs (4) had a large
sample size, although it also had a placebo run-in period and
only treated patients for 2 wk. Two of the RCTs (1–2) were
placebo controlled and met 7–8 Rome criteria, although these
trials had very small sample sizes. The fourth study had no
control group other than “no therapy” (3).
In the placebo-controlled crossover trial of docusate cal-
cium versus placebo, there were no differences in stool fre-
quency or consistency (1). In the parallel study of doscusate
calcium and two doses of docusate sodium versus placebo,
docusate calcium increased stool frequency (3). No regimen
improved stool consistency. The crossover study of docusate
sodium versus placebo showed significant improvement in
stool frequency and subjective global assessment of symp-
toms with docusate sodium (2). In the comparison of docusate
sodium with psyllium, psyllium caused a significant increase
in stool frequency compared with docusate sodium during the
second week (4). Given the small sample sizes and conflicting
results in placebo-controlled trials, it is not possible to make
a recommendation about the efficacy of stool softeners as
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Table 2.7. Trial Characteristics: Stool Softeners
Outcomes Quality
Trial Study Type Treatment Dose Control No. Duration Measured Score
1 (Castle) Crossover DCS 240 mg bid Placebo 15 3 wks each after 2 wk run-in SF, SC 4
Result: No significant difference in stool frequency/wk (4.3 vs 4.1, respectively; p > 0.05) or stool consistency between DCS and
placebo.
2 (Hyland) Crossover DSS 100 mg tid Placebo 34 4 wks each SF, SGA 4
Result: Significant improvement in percentage of patients with increased stool frequency (1 more stool/wk) and Subjective
Global Assessment of Effectiveness with DSS compared with placebo.
3 (Fain) Parallel DCS 240 mg/d None 46 3 wks after 2 wk placebo run-in SF, SC 3
DSS 100 mg/d
DSS 100 mg/d
Result: Significant improvement in stool frequency/wk with DCS compared with placebo (2.83/wks vs 1.75/wks, respectively;
p < 0.05). No significant difference was observed with either dose of DSS. No significant change in stool consistency was observed
with any regimen.
4 (McRorie) Parallel DSS 100 mg bid Psyllium 5.1 gm bid 170 2 wks after 2 wks placebo run-in SF 5
Result: Significant improvement in stool frequency/wk with psyllium compared with DSS (3.5/wk vs 2.9/wk, respectively; p < 0.05)
during wk 2.
DSS: docusate sodium (Colace); DCS: docusate calcium (Surfak); SF = stool frequency; SC = stool consistency; SGA = subjective global assessment of bowel habits.
treatment for CC symptoms. There were no statistically sig-
nificant differences in adverse effects among subjects given
stool softeners and placebo.
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2.8 Effectiveness of Osmotic Laxatives in the
Treatment of Chronic Constipation
Polyethylene glycol (PEG) is effective at increasing stool fre-
quency and stool consistency in patients with CC (Grade A
recommendation). Lactulose is effective at increasing stool
frequency and stool consistency in patients with CC (Grade
A recommendation). There are insufficient data to make a
recommendation about the effectiveness of magnesium hy-
droxide in patients with CC (Grade B recommendation).
Osmotic laxatives contain poorly absorbed ions or
molecules and create an osmotic gradient within the intesti-
nal lumen, thereby retaining water in the intestinal lumen.
Osmotic laxatives available in the United States include lactu-
lose (e.g., Kristalose), polyethylene glycol (e.g., Miralax),
and magnesium hydroxide (e.g., milk of magnesia). These
agents are FDA approved for the treatment of constipation
(e.g., Kristalose) or occasional constipation (e.g., milk of
magnesia). Polyethylene glycol is approved for the treat-
ment of occasional constipation and may be used for 2 wk or
less.
Multiple electrolyte abnormalities (e.g., hypermagne-
semia, hyperphosphatemia, hypercalcemia, hyponatremia,
hypokalemia), hypovolemia, and diarrhea have been reported
with these agents, although the precise incidence of these ad-
verse events is unclear (1). Per FDA-approved prescribing
information, high doses of polyethylene glycol may produce
diarrhea and excessive stool frequency, especially in nursing
home patients, and nausea, abdominal bloating, cramping,
and flatulence may occur.
Lactulose
Trial characteristics of the three RCTs of lactulose are shown
in Table 2.8.1 (2–4).
All three trials are placebo-controlled, and two trials
demonstrate high quality study design (3–4). Only one trial
entered a substantial number of patients (n = 103) (4). In
the first of these studies (2), both lactulose and placebo sig-
nificantly increased stool frequency compared with baseline
values, and the effect of lactulose was numerically greater
than the effect of placebo (2). Lactulose, but not placebo,
significantly improved stool consistency. In the second trial
(3), the mean number of bowel movements/day was signifi-
cantly greater with lactulose than with placebo and lactulose
relieved all assessed symptoms more often than did placebo.
Patients in the lactulose group had significantly fewer fecal
impactions (n = 6) than did patients in the placebo group
(n = 66). In the third trial, the “success rate” with lactulose
(80%) was significantly greater than with placebo (60%) (4).
Even though there are only three trials, two are of high qual-
ity and the results all favor lactulose. One study reported that
significantly more patients experienced abdominal pain with
lactulose.
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Table 2.8.1. Trial Characteristics: Lactulose
Type Outcomes Quality
Trial Study Treatment Dose Control No. Duration Measured Score
2 (Bass) Parallel Lactulose 60 mL/d Placebo 24 1 wk after 1 wk baseline SF, SC 3
Results: Stool frequency/wk increased more with lactulose compared with placebo (4.5/wk vs 2.8/wk, respectively; p < 0.05). Stool
consistency (Likert scale measurement) improved significantly more with lactulose than with placebo (4.3 vs 3.8, p = 0.01).
3 (Sanders) Parallel Lactulose 30 mL/d Placebo 47 12 wks after 2 wk baseline SF, Sxs, FI 4
Results: Stool frequency/day was significantly greater with lactulose compared with placebo (0.6–0.8/d vs 0.5–0.6/d, respectively;
p < 0.05). Fecal impactions were significantly lower with lactulose compared with placebo (6 vs 66, respectively; p < 0.05). Multiple
symptoms of constipation were significantly improved with lactulose compared with placebo.
4 (Wesselius-De Casparis) Parallel Lactulose 15–30 mL/d Placebo 103 3 wks after 2 wk baseline “Success rate” 4
Result: “Success rate” was significantly greater for lactulose compared with placebo (80% vs 60%, respectively; p < 0.05).
SF = stool frequency; SC = stool consistency; Sxs = miscellaneous CC symptoms, including straining; FI = fecal impaction.
Polyethylene Glycol
There are five placebo-controlled RCTs of polyethylene gly-
col (PEG), and two RCTs comparing PEG and lactulose
(Table 2.8.2) (5–11).
Of the five placebo-controlled trials of PEG (4–8), four
are high quality by Jadad criteria and four met 8 or more
Rome criteria (5–8). A sixth trial compared PEG with lactu-
lose and placebo in patients with opiate-induced constipation
(10), and the seventh (a high quality trial) compared PEG and
Table 2.8.2. Trial Characteristics: PEG
Outcomes Quality
Trial Study Type Treatment Dose Control No. Duration Measured Score
5 (Andorsky) Crossover PEG (Colyte) 8–16 oz/d Placebo 32 5 days with 2 day
WO
SF, SC 5
Result: Stool frequency significantly improved compared with placebo with either dose of PEG. Stool consistency improved
significantly with the 16 oz/d dose of PEG vs placebo.
6 (Cleveland) Crossover PEG (Miralax) 17 g/d in Placebo 23 14 days each after SF, SC, 3
250 mg 7 days EOD 3
Results: Stool frequency (1 BM/d vs 0.5 BM/d, respectively), stool consistency, ease of defecation, cramping were significantly
improved with PEG compared with placebo.
7 (Corazziari) Parallel PEG 17.5 g in
250 mL bid
Placebo 48 8 wks after 4 wk
placebo RI
SF, SC 5
Result: Stool frequency significantly improved with PEG compared with placebo (4.8/wks vs 2.8/wks, respectively; p < 0.05). Stool
consistency and straining also improved significantly with PEG compared with placebo.
8 (Corazziari) Parallel PEG (Normopeg) 17.5 g in
250 mL bid
Placebo 70 20 wks after 4
wks PEG RI
SF 5
Result: Stool frequency significantly improved with PEG compared with placebo (7.4/wk vs 5.4/wk, respectively; p < 0.05).
9 (DiPalma) Parallel PEG (Miralax) 17 gm/d in Placebo 151 2 wk after 1 wk SF, SC, 4
8 oz baseline EOD, SGA
Result: Stool frequency significantly improved with PEG compared with placebo (4.5/wk vs 2.7/wk, respectively; p < 0.05). Stool
consistency and ease of defecation were significantly improved with PEG compared with placebo.
10 (Freedman) Crossover PEG (Go-Lytely) 240 mL/d Placebo or Lactulose 57 2 wk each after1 SF, SC, 3
wk RI EOD
Result: Non-hard stools were significantly more frequent with lactulose or PEG compared with placebo (data from figure).
11 (Attar) Parallel PEG (Movicol) 13 gm in
125 mL bid
Lactulose 10 g bid 99 4 wk SF 5
Result: Stool frequency was significantly higher with PEG compared with lactulose (1.3/d vs 0.9/d, respectively; p < 0.05). Straining
and overall effectiveness was significantly improved with PEG compared with lactulose.
SF = stool frequency; SC = stool consistency; EOD = ease of defecation; SGA = subjective global assessment of bowel habits.
lactulose (11). Four of the trials were of parallel design (7–9,
11) and four enrolled more than 50 patients (8–11). The study
duration was ≥ 8 wk in only two trials (7–8).
In the five placebo-controlled trials, PEG resulted in in-
creased stool frequency and improvement in stool consis-
tency compared with placebo (5–9). In the sixth study, both
PEG and lactulose produced more “non-hard” stools than did
placebo, with PEG producing the loosest stools (10). In the fi-
nal study, stool frequency was significantly greater with PEG
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compared with lactulose, straining occurred significantly less
often with PEG, and overall effectiveness was significantly
better with PEG (11). Adverse events were not adequately
reported in most trials, and no statistically significant differ-
ences in adverse events were reported among patients taking
PEG, placebo, or lactulose. Discontinuation of medication
because of diarrhea was not reported in any trials. Incidence
of diarrhea in PEG-treated patients ranged from 2–40% in
individual trials. Per FDA-approved prescribing information,
high doses of PEG may be associated with diarrhea and exces-
sive stool frequency, especially in nursing home patients, and
nausea, abdominal bloating, cramping, and flatulence may
occur. Multiple electrolyte abnormalities (e.g., hypermag-
nesemia, hyperphosphatemia, hypercalcemia, hyponatremia,
hypokalemia), and hypovolemia have been reported with os-
motic laxatives (1).
Magnesium Hydroxide
Only one, very low quality trial evaluated magnesium hy-
droxide in comparison with “laxamucil,” a compound not
available in the United States (12). In this crossover study, 64
patients were treated for 8 wk with one treatment and then
crossed over to the other treatment. There were 2.8 more
defecations and one less bisacodyl dose used over the last
4 wk with magnesium hydroxide. No reporting of adverse
events was provided in this trial. Given the poor quality of
study design, Task Force members felt that it was not possible
to make any recommendation about magnesium hydroxide as
treatment for constipation.
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2.9 Effectiveness of Stimulant Laxatives in the
Treatment of Chronic Constipation
There are insufficient data to make a recommendation about
the effectiveness of stimulant laxatives in patients with CC
(Grade B recommendation).
Stimulant laxatives include compounds containing senna
(e.g., Senokot, ExLax) or bisacodyl (e.g., Dulcolax,
Correctol, Carter’s Pills). These agents are FDA approved
for the treatment of occasional constipation. The mechanism
of their action is believed to involve stimulation of sensory
nerve endings upon their contact with colon mucosa, and they
may also inhibit water absorption by affecting epithelial trans-
port of water and electrolytes. Abdominal discomfort, elec-
trolyte imbalances, allergic reactions and hepatotoxicity have
been reported with these agents (1). Senna-containing com-
pounds also have been associated with melanosis coli. Al-
though cathartic colon (a syndrome characterized by colonic
dilatation and loss of haustration) has been reported in pa-
tients using stimulant laxatives, this entity has not been re-
ported in long-term users of currently available stimulant lax-
atives (1). It is arguable if the long-term use of stimulant
laxatives induces any permanent injury to either the colonic
mucosa or the enteric nervous system (1).
Four RCTs of these compounds were found (Table 2.9)
(2–5). There are no placebo-controlled trials of stimulant lax-
atives, and study design was low quality (1–2 out of 5) in all
studies. The comparator agent in two studies is not available
in the United States (2, 4). In the first three trials, there was
no difference between the stimulant laxative and control lax-
ative in stool frequency or consistency (2–4). In the last study
(5), 58% of patients taking lactulose were passing a normal
stool by day 7 compared with 42% of patients taking the
stimulant laxative. Given the poor quality of study design, it
is not possible to make any recommendation about the effi-
cacy of stimulant laxatives for the treatment for constipation.
There were no statistically significant differences in adverse
events between stimulant laxatives and control agents, al-
though adverse events were not reported adequately in most
studies.
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Table 2.9. Trial Characteristics: Stimulant Laxatives
Study Outcomes Quality
Trial Type Treatment Dose Control No. Duration Measured Score
2 (MacLennan) Parallel Senna 2 tabs/d Na Picosulfate 50 2 wk SF, SC 2
Results: Stool frequency was similar with senna and sodium picosulphate (4.4/wk vs 5.0/wk). Loose or unformed stools were more
common with sodium picosulfate compared with senna (43% vs 21%, respectively; p < 0.05).
3 (McCallum) Parallel Senna (Senokot) 10 mL daily or
3x/wk
Bran 10 gm as 3
biscuits or
unrefined
23 3 wk each SF, SC 1
Results: Stool frequency was similar with either bran preparation compared with sennokot (5.6/3 wk and 5.2/3 wk vs 5.8/wk,
respectively).
4 (Rider) Crossover Bisacodyl 10 mg/d Bisoxatin 60 mg/d 51 4 wk each SF, SC 2
Results: Stool consistency and stool frequency was similar with bisacodyl compared with bisoxatin (2.1/d vs 1.7/d, respectively).
5 (Connolly) Crossover “Irritant Laxative” ? Lactulose 30 mL/d 194 1 wk each and 1
wk without
SC 2
Results: Percentage of patients passing normal stools by day 7 was significantly greater with lactulose compared with “irritant” laxative
(58% vs 42%, respectively; p < 0.05).
SF = stool frequency; SC = stool consistency.
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Trial Study Type Treatment Dose Control No. Duration Measured Score
1 Parallel Tegaserod 2 mg bid Placebo 1264 12 wk ∗CSBM 5
6 mg bid SF, SC
Global improvement
Result: Percentage of patients with one additional complete spontaneous bowel movement per week was significantly greater with
tegaserod compared with placebo (41% vs 25%, respectively; p < 0.05). Percentage of patients with significant improvement in global
satisfaction with their bowel habits was significantly greater with tegaserod compared with placebo (40% vs 30%, respectively;
p < 0.05). Stool frequency, stool consistency, and straining (Likert scale measurement) were significantly improved with
tegaserod compared with placebo.
2 Parallel Tegaserod 2 mg bid Placebo 1348 12 wk ∗CSBM 5
6 mg bid SF, SC
Global Improvement
Result: Percentage of patients with one additional complete spontaneous bowel movement per week was significantly greater with
tegaserod compared with placebo (44% vs 25%, respectively; p < 0.05). Percentage of patients with significant improvement in global
satisfaction with their bowel habits was significantly greater with tegaserod compared with placebo (44% vs 31%, respectively;
p < 0.05). Stool frequency, stool consistency, and straining (Likert scale measurement) were significantly improved with tegaserod
compared with placebo.
CSBM = complete spontaneous bowel movement.
SF = stool frequency; SC = stool consistency; Global Improvement = subjective global improvement in satisfaction with bowel habits.
2.10 Effectiveness of Tegaserod in the Management of
Chronic Constipation
Tegaserod is effective at improving the frequency of complete
spontaneous bowel movements, straining, stool frequency,
and stool consistency in patients with CC (Grade A recom-
mendation).
Tegaserod is an agonist of the 5-HT4 (serotonin) presy-
naptic receptor. Through its action on 5-HT4 receptors in the
enteric nervous system, tegaserod stimulates the peristaltic
reflex, increases colonic motility, decreases visceral hyper-
sensitivity, and facilitates secretion into the colonic lumen
(1–3). Tegaserod is FDA-approved for the treatment of IBS
with constipation in women and for the treatment of CC in





























* P < 0.0001.  Responder = increase of ≥ 1 CSBM/week.
Johanson JF, et al. Clin Gastroenterol Hepatol . 2004; 2:796 -805.
Kamm MA, et al. Am J Gastroenterol . 2005;100:372-82.
Figure 2.10.1. Percentage of responders with an increase in complete spontaneous bowel movements among male and female CC patients
<65 years with tegaserod and placebo.
men and women younger than 65 years of age. Diarrhea is
associated with tegaserod use in CC patients.
Two RCTs have evaluated the effectiveness of tegaserod in
the management of CC (4–5) (Table 2.10.1). Both of these
trials were high quality trials (5/5 Jadad criteria and 13/14
Rome criteria), and each trial enrolled over 1000 patients.





























* P < 0.0001.  Responder = increase of one point in a five point Likert scale measuring global satisfaction with bowel habits.
Johanson JF, et al. Clin Gastroenterol Hepatol . 2004; 2:796 -805.
Kamm MA, et al. Am J Gastroenterol . 2005;100:372-82
Figure 2.10.2. Percentage of responders with improved global satisfaction with their bowel habits among male and female CC patients
<65 years with tegaserod and placebo.
trials were female and Caucasian, respectively. Patients had
a mean age of 46 years, and met modified Rome II criteria
for the diagnosis of constipation (4, 5).
Both trials assessed the efficacy of tegaserod in doses
of 2 mg BID and 6 mg BID for improvement of complete
spontaneous bowel movements (primary objective), stool fre-
quency, stool form, straining, sense of complete evacuation,
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and global satisfaction with bowel habits. Based on the
prescribed primary end point (i.e., an increase of one
complete spontaneous bowel movement/wk), 16–19% more
tegaserod-using patients younger than 65 years were re-
sponders compared with placebo-using patients younger
than 65 years (Fig. 2.10.1). Tegaserod 6 mg BID also in-
creased spontaneous bowel movements (mean increase of
2 bowel movements/wk) and produced significant improve-
ments in stool form and straining. Tegaserod-using pa-
tients younger than 65 years were 10–13% more likely to
demonstrate improvement in global satisfaction with bowel
habits compared with similarly aged placebo-using patients
(Fig. 2.10.2).
Tegaserod 6 mg BID was associated with a statistically sig-
nificant increase in diarrhea compared with placebo (6.6% vs
3.0%), however, there was no statistically significant differ-
ence in discontinuation of study drug because of diarrhea,
in tegaserod-using patients (<1%) and placebo-using pa-
tients. New FDA-approved prescribing information includes
a precaution that ischemic colitis has been reported among
tegaserod-treated patients. When evaluating this precaution,
physicians may wish to consider the following data (6): (1) in
clinical trials, no cases of ischemic colitis have been reported
among >11,400 tegaserod-treated patients and only one case
of probable ischemic colitis has been reported among >2500
placebo-treated patients; (2) in post-marketing surveillance,
the rate of ischemic colitis in tegaserod-treated patients is
∼10 per 100,000 patient-years of follow-up compared with
a rate of ∼8 per 100,000 patient-years in the general popu-
lation and a rate of 44–47 per 100,000 patient-years in the
IBS population. Because of these data, the FDA did not issue
a “warning,” which is defined as “reasonable evidence of an
association between a drug (e.g., tegaserod) and an adverse
event (e.g., ischemic colitis)” (6).
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2.11 Effectiveness of Herbal Supplements, Alternative
Therapies, Lubricants and Combination Laxatives in the
Management of Chronic Constipation
There are insufficient data to make a recommendation about
the effectiveness of herbal supplements, lubricants, alterna-
tive therapies, or combination laxatives in patients with CC
(Grade C recommendation).
There are no published RCTs examining the efficacy of
herbal supplements (e.g. aloe) available in the United States
in patients with CC. A single RCT examined an aloe and
psyllium-based treatment that is not available in the United
States (1). This study demonstrated a significant improvement
in stool frequency and stool consistency, although the study
design was poor and may have led to biased results. There are
no published RCTs on the efficacy of mineral oil, a lubricant,
in adult patients with CC. RCTs (2–3) have evaluated the
efficacy of mineral oil for the treatment of constipation in
pediatric populations, and these studies indicate that mineral
oil was superior to senna-based laxatives for stool frequency
and stool consistency (3), but inferior to osmotic laxatives (2).
There are several combination laxatives available, including
senna plus psyllium and senna plus docusate, however, there
is no RCT evidence examining the efficacy of these products
in adult CC patients.
Biofeedback has been examined in multiple trials as a
therapy for pelvic floor dyssynergia or outlet-type con-
stipation (4), however, there are no placebo-controlled or
sham-controlled randomized trials of these therapies in adult
CC patients. No biofeedback technique (e.g., peri-anal EMG
biofeedback, intra-anal EMG biofeedback, balloon defe-
cation training, intrarectal balloon distention training) has
proved to be consistently more effective than another biofeed-
back technique in an appropriately designed study. Available
studies (4) indicate that biofeedback improves physiologic
outcomes (e.g., propulsive force of evacuation) and clinical
outcomes (e.g., stool frequency) compared with baseline data.
Given the absence of RCT data in adults with CC, Task
Force members concluded that these data were inadequate to
make a recommendation about the efficacy or safety of these
therapies.
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